Dog,
Cardiogenics' cash position is what prompted my Random Musings post. IMO the company's cash on hand ($272K on April 30, 2012) has been reduced to less than $100K in the past Q (due in part to the company's $187K G&A quaterly expenses).
Consequently, IMO the company needs funding to continue to operate as a going concern. I anticipate Cardiogenics will complete and announce a PIPE sufficient in size to fund the company through completion of the larger FDA study. And, I believe Cardiogenics will announce this PIPE prior to filing their next 10Q.
Ante
